Wu Y, Mikulski S M, Ardelt W, Rybak S M, Youle R J
Biochemistry Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
J Biol Chem. 1993 May 15;268(14):10686-93.
Onconase, or P-30, is a protein initially purified from extracts of Rana pipiens oocytes and early embryos based upon its anticancer activity both in vitro and in vivo. It is a basic single-chain protein with an apparent molecular mass of 12,000 daltons and is homologous to RNase A. In cultured 9L glioma cells, onconase inhibits protein synthesis with an IC50 of about 10(-7) M. The inhibition of protein synthesis correlates with cell death determined by clonogenic assays. 125I-Labeled onconase binds to specific sites on cultured 9L glioma cells. Scatchard analysis of the binding data shows that onconase appears to bind to cells with two different affinities, one with a Kd of 6.2 x 10(-8) and another of 2.5 x 10(-7) M. Each cell could bind about 3 x 10(5) molecules of onconase at each of the two affinity sites. The low affinity Kd is similar to the IC50 for onconase toxicity. Onconase also demonstrates a saturability of cytotoxicity at a concentration that would saturate the low affinity binding site. Incubation at 4 degrees C increased the binding of onconase to cells relative to 37 degrees C binding and also increased the sensitivity of cells to onconase toxicity, indicating that receptor binding may be an initial step in cell toxicity. Onconase cytotoxicity can be blocked by metabolic inhibitors, NaN3 and 2-deoxyglucose, and cytotoxicity is potentiated 10-fold by monensin. Ribonuclease activity appears necessary for onconase toxicity because alkylated onconase, which only retains 2% of the ribonuclease activity, was at least 100-fold less potent in inhibiting protein synthesis in cells. Onconase inhibition of protein synthesis in 9L cells coincides with the degradation of cellular 28 S and 18 S rRNA. In contrast to RNase A, onconase is resistant to two RNase inhibitors, placental ribonuclease inhibitor and Inhibit-Ace. Northern hybridization with placental ribonuclease inhibitor cDNA probe indicates that 9L glioma cells contain endogenous placental ribonuclease inhibitor mRNA. Based on these results, we propose that onconase toxicity results from onconase binding to cell surface receptors, internalization to the cell cytosol where it degrades ribosomal RNA, inhibiting protein synthesis and causing cell death.
抗癌酶,即P - 30,是一种最初从豹蛙卵母细胞和早期胚胎提取物中纯化出来的蛋白质,基于其在体外和体内的抗癌活性。它是一种碱性单链蛋白质,表观分子量为12,000道尔顿,与核糖核酸酶A同源。在培养的9L胶质瘤细胞中,抗癌酶抑制蛋白质合成,IC50约为10(-7) M。蛋白质合成的抑制与克隆形成试验所确定的细胞死亡相关。125I标记的抗癌酶与培养的9L胶质瘤细胞上的特定位点结合。对结合数据的Scatchard分析表明,抗癌酶似乎以两种不同的亲和力与细胞结合,一种Kd为6.2×10(-8),另一种为2.5×10(-7) M。每个细胞在两个亲和位点上每个位点可结合约3×10(5)个抗癌酶分子。低亲和力Kd与抗癌酶毒性的IC50相似。抗癌酶在使低亲和力结合位点饱和的浓度下也表现出细胞毒性的饱和性。与37℃结合相比,4℃孵育增加了抗癌酶与细胞的结合,也增加了细胞对抗癌酶毒性的敏感性,表明受体结合可能是细胞毒性的初始步骤。抗癌酶的细胞毒性可被代谢抑制剂NaN3和2 - 脱氧葡萄糖阻断,莫能菌素可使细胞毒性增强10倍。核糖核酸酶活性似乎是抗癌酶毒性所必需的,因为烷基化的抗癌酶仅保留2%的核糖核酸酶活性,其抑制细胞内蛋白质合成的效力至少低100倍。抗癌酶对9L细胞中蛋白质合成的抑制与细胞28 S和18 S核糖体RNA的降解一致。与核糖核酸酶A不同,抗癌酶对两种核糖核酸酶抑制剂,即胎盘核糖核酸酶抑制剂和Inhibit - Ace具有抗性。用胎盘核糖核酸酶抑制剂cDNA探针进行的Northern杂交表明,9L胶质瘤细胞含有内源性胎盘核糖核酸酶抑制剂mRNA。基于这些结果,我们提出抗癌酶毒性是由于抗癌酶与细胞表面受体结合,内化到细胞胞质溶胶中,在那里它降解核糖体RNA,抑制蛋白质合成并导致细胞死亡。